Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549429 · ClinicalTrials.gov registry record · NA
Tegaderm vs. EyeGard for Eye Protection
A NA study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 159
- Enrollment target
NCT03549429: Completed NA study, sponsored by Tufts Medical Center.
NCT03549429 is a NA study that has completed, run by Tufts Medical Center. The registered enrollment target is 159 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03549429, a NA study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 159 participants
- Enrollment target
Study Summary
This study compares TegadermTM and EyeGard® in general anesthesia.
Primary Outcome
The amount of erythema caused upon removal of the tape is the primary outcome of interest. Investigators will use the following 0-3 tape-associated skin index grading scale to grade eyelid erythema: 0- no erythema 1. mild erythema 2. moderate erythema 3. severe erythema The primary outcome will then be converted to a binary scale (0= no erythema, 1= erythema) for the purposes of analysis.
Interventions
- DEVICE Medical tapes: TegadermTM and EyeGard®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2018-07-20 |
| Phase | NA |
What the finished NCT03549429 record still lists
NCT03549429 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Medical tapes: TegadermTM and EyeGard® is the first listed.
NCT03549429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03549429 about?
NCT03549429 is a clinical study titled "Tegaderm vs. EyeGard for Eye Protection". This study compares TegadermTM and EyeGard® in general anesthesia.
What is the current status of trial NCT03549429?
This trial is currently completed. It is a NA study. The enrollment target is 159 participants. The study started on 2018-06-01. Estimated completion is 2018-07-20.
What interventions are being tested in trial NCT03549429?
The interventions under investigation include: Medical tapes: TegadermTM and EyeGard® (DEVICE).
Who is sponsoring clinical trial NCT03549429?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03549429's enrollment target sits among peer trials
159 654th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI